Medicine
Auryxia 210 mg tablet
Auryxia 210 mg tablet is a prescription medicine containing Tetraferric tricitrate for oral use, marketed by Akebia Therapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59°…
Key facts
- Active ingredient (INN)
- Tetraferric tricitrate
- Brand
- Auryxia
- Strength
- 210 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 200 tablets
- Marketing authorisation holder
- Akebia Therapeutics
- Manufacturer
- Akebia Therapeutics
- Origin register
- US FDA, United States
- Storage
- Store at 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59° to 86°F). Protect from moisture.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- B03AB06 Tetraferric tricitrate
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 17 September 2014
- Identifiers
- RxCUI 1594680, 1596023DailyMed set ID aadd18e0-3752-11e4-8510-0800200c9a66NDC 59922-631Application NDA205874
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 200 tablet, film coated in 1 bottle | 59922-631-01 | Akebia Therapeutics | 17 September 2014 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Tetraferric tricitrate 210 mg tablet.
Clinical summary
Tetraferric tricitrate is a parenteral iron replacement indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis, among other approved uses. It is available as tablets for oral use. MedsAcross supplies Tetraferric tricitrate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Tetraferric tricitrateFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Auryxia prescribing information (Akebia Therapeutics) · U.S. National Library of Medicine, DailyMed
Need Auryxia 210 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.